Navigation Links
ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition
Date:12/3/2008

RANCHO CORDOVA, Calif., Dec. 3 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that the call in number for its conference call on Thursday, December 4, to discuss its announcement regarding a management transition at the Company is (800) 860-2442 (domestic) or (412) 858-4600 (international), passcode ThermoGenesis.

The conference call will begin at 5:30 a.m., Pacific Standard Time (8:30 a.m., Eastern Standard Time). A webcast of the conference call will also be available on the Company's website at http://www.thermogenesis.com/investors- webcasts-and-calls.aspx.

A replay of the call will be available by calling (877) 344-7529 (domestic), or (412) 317-0088 (international), passcode 385107#, or via the Company's website.

About ThermoGenesis Corp.

ThermoGenesis Corp. (http://www.thermogenesis.com) is a leading supplier of innovative products and services that process and store adult stem cells for treatment of disease and injury.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

     ThermoGenesis Corp.
     Web site:http://www.thermogenesis.com
     Contact: Investor Relations
     +1-916-858-5107, or
     ir@thermogenesis.com

'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
2. ThermoGenesis Corp. Reports First Quarter 2008 Results
3. Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
4. ThermoGenesis Announces Filing of 510(k) Application for MarrowXpress
5. ThermoGenesis Announces 10 New BioArchive(R) System Distributors
6. ThermoGenesis Reports First Quarter 2009 Results
7. ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones
8. ThermoGenesis Corp. Schedules Conference Call/Webcast to Discuss Management Transition
9. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
10. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
11. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Washington, DC (PRWEB) , ... March 23, 2017 , ... ... for Dental Choice has helped score a major victory in Europe for public health ... lead. , Based on rigorous scientific research and the overwhelming support of ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, the largest multi-specialty ... payment system, to expand its focus on patient care by providing an advanced ... , “At Ogden Clinic, we are working to become a different type of ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider of ... expression in circulating tumor cells using microfluidic western blotting” in Nature Communications on ... Vortex technology to capture CTCs and a microfluidic single-CTC resolution Western blot ...
(Date:3/22/2017)... ... March 22, 2017 , ... Sam ... insurance assistance, financial planning, and related services to residents of the region, is ... awareness of threatened species and wild lands. , Endangered Species International is committed ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... and this tool bypasses that. Healthcare facilities across the country are always ... offer their clients and hospitals, across the country, an efficient and quick way ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 22, 2017  Ablation is the minimally invasive ... range of purposes, from cancerous or diseased tissue ... tissue in atrial fibrillation and others. The growing ... researchers to innovate and improvise existing ablation technologies ... device global market is expected to grow at ...
(Date:3/22/2017)... 22, 2017 TapImmune, Inc. ... the development of innovative peptide and gene-based immunotherapeutics ... today announced that it will participate in two ... Glynn Wilson , Chairman and CEO of ... business, clinical pipeline and partnering opportunities for its ...
(Date:3/22/2017)... March 22, 2017 Piramal Pharma ... (CDMO), held a special event to introduce the new ... Lexington, Kentucky . The inaugural event was ... Chairman Ajay Piramal, and Piramal Pharma Solutions CEO, ... ...
Breaking Medicine Technology: